Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

FBLG

+ Watchlist+ Portfolio

FibroBiologics, Inc.

Regulated industrySells to businessesDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$0.84
52-Week Range
$0.62 – $9.60
Market Cap
$7.46M
P/E (TTM)
—
EPS (TTM)
-2.51
Dividend Yield
0.00%
Advanced Metrics
Price/Book
3.82
PEG Ratio
—
Return on Equity
-1696.90%
Return on Assets
-127.15%
Gross Margin
0.00%
Operating Margin
0.00%
Profit Margin
0.00%
Current Ratio
1.22
Debt/Equity
0.70
Total Debt
$1.27M
Free Cash Flow
$-7.64M
Revenue Growth
—
Earnings Growth
—
Enterprise Value
$7.66M

Market Snapshot

About

FibroBiologics, Inc. is a clinical-stage biotechnology company focused on developing cell-based therapies using fibroblast cells. The company's proprietary platform technology leverages the regenerative properties of fibroblasts to treat degenerative diseases, cancer, and wound healing applications. FibroBiologics is developing a pipeline of therapeutic candidates targeting conditions including multiple sclerosis, degenerative disc disease, and various oncology indications. The company's approach seeks to harness the immunomodulatory and tissue-regenerative capabilities of fibroblast cells to address unmet medical needs across multiple therapeutic areas.